MOUNTAIN VIEW, Calif., Jan. 27, 2012 /PRNewswire/ -- Pinpoint Genomics, Inc. announced the publication of key data relating to its Pinpoint Dx Lung Assay in the journal The Lancet, and the availability of its Pinpoint Dx Lung Assay to clinicians and patients exclusively through the company’s laboratory in Mountain View, CA.
The report in The Lancet describes the development of the assay based on specimens from 361 patients who underwent surgery at the University of California, San Francisco (UCSF), as well as the results of the two largest independent, blinded studies to evaluate the clinical validity of a multi-gene molecular diagnostic assay for early stage lung cancer. The two validation studies, conducted by the Kaiser Permanente Division of Research and the China Clinical Trials Consortium, involved 433 patients from northern California and 1,006 patients from several leading cancer centers in China, respectively.
The Pinpoint Dx Lung assay is run on surgical specimens that undergo routine handling by pathology laboratories, making it immediately available to virtually all patients, and is offered through Pinpoint’s Clinical Laboratory Improvement Amendment-certified laboratory.
For information on how to send a sample to the Pinpoint Genomics laboratory, visit the company’s website at www.pinpoint genomics.com, and click on “Order Test” and download the Test Order Form, which contains all of the information necessary for physicians to order the test. The test is currently not available in all states. For additional information or questions, physicians can call the laboratory at 888-279-5088.
About Pinpoint Genomics and the Pinpoint Dx LungAssay
The Pinpoint Dx LungAssay is a molecular diagnostic assay that differentiates between patients at high, intermediate or low risk of early death after surgery to remove a non-squamous, non-small cell lung cancer, the most common form of lung cancer, in patients with early stage disease.
Pinpoint Genomics, Inc. is a privately held cancer company focused on the development and commercialization of molecular assays and genomic-based clinical laboratory services to provide individualized information to patients and clinicians.
Pinpoint Genomics is also developing additional assays for patients with lung and other cancers. For more information, please visit www.pinpointgenomics.com , or fax inquiries to (866) 714-9299.
The Pinpoint Genomics logo and Pinpoint Dx Lung Assay are trademarks of Pinpoint Genomics, Inc.
SOURCE Pinpoint Genomics, Inc.
